Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

被引：0

作者：

Karvouni, Maria ^{[1
]}

Zhou, Heyue ^{[2
]}

Kathleen, Arnika ^{[1
]}

Ma, Qiangzhong ^{[2
]}

Baloch, Alamdar H. ^{[1
]}

Zhu, Tong ^{[2
]}

Zhang, Hong ^{[2
]}

Gilljam, Mari ^{[3
]}

Lundqvist, Andreas ^{[4
]}

Kaufmann, Gunnar F. ^{[2
]}

Alici, Evren ^{[1
]}

机构：

[1] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden

[2] Sorrento Therapeut Inc, San Diego, CA USA

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Inst, Dept Ocol Pathol, Stockholm, Sweden

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-127893

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1848

引用

页数：2

共 50 条

[31] DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
Priya Choudhry
Margarette C. Mariano
Huimin Geng
Thomas G. Martin
Jeffrey L. Wolf
Sandy W. Wong
Nina Shah
Arun P. Wiita
Leukemia, 2020, 34 : 938 - 941
[32] Serological Investigation in a Multiple Myeloma Patient receiving Daratumumab (Anti-CD38)
Oldfield, L.
Ison, T.
Lau, W.
TRANSFUSION, 2016, 56 : 135A - 136A
[33] 212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study
Quelven, Isabelle
Monteil, Jacques
Sage, Magali
Saidi, Amal
Mounier, Jeremy
Bayout, Audrey
Garrier, Julie
Cogne, Michel
Durand-Panteix, Stephanie
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (07) : 1058 - 1065
[34] CD38 Enzymatic Activity Modulates Drug Susceptibility in Multiple Myeloma Cells
Kawano, Yawara
Bai, Junzhe
Kushima, Saki
Hata, Hiroyuki
Yasunaga, Jun-ichirou
BLOOD, 2024, 144 : 6833 - 6833
[35] Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma
Lee, Hyun Tae
Kim, Yujin
Park, Ui Beom
Jeong, Tae Jun
Lee, Sang Hyung
Heo, Yong-Seok
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 536 : 26 - 31
[36] EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
Chemlal, Djamila
Varlet, Emmanuel
Machura, Amelie
Ovejero, Sara
Requirand, Guilhem
Robert, Nicolas
Cartron, Guillaume
Alaterre, Elina
Bret, Caroline
Vincent, Laure
Herbaux, Charles
Cavalli, Giacomo
Bruyer, Angelique
De Boussac, Hugues
Moreaux, Jerome
LEUKEMIA, 2023, 37 (9) : 1925 - 1928
[37] EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
Djamila Chemlal
Emmanuel Varlet
Amelie Machura
Sara Ovejero
Guilhem Requirand
Nicolas Robert
Guillaume Cartron
Elina Alaterre
Caroline Bret
Laure Vincent
Charles Herbaux
Giacomo Cavalli
Angélique Bruyer
Hugues De Boussac
Jerome Moreaux
Leukemia, 2023, 37 : 1925 - 1928
[38] EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma
Chemlal, Djamila
Varlet, Emmanuel
Machura, Amelie
Requirand, Guilhem
Robert, Nicolas
Alaterre, Elina
Vincent, Laure
Herbaux, Charles
Cavalli, Giacomo
Bruyer, Angelique
De Boussac, Hugues
Moreaux, Jerome
BLOOD, 2022, 140 : 4220 - 4221
[39] Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab
van der Veer, Michael S.
de Weers, Michel
van Kessel, Berris
Wittebol, Shulamiet
Bakker, Joost M.
Parren, Paul W. H. I.
Lokhorst, Henk M.
Mutis, Tuna
BLOOD, 2010, 116 (21) : 1262 - 1262
[40] PHF19 promotes multiple myeloma cell resistant to daratumumab/isatuximab via upregulation in immunosuppressive microenvironment and reduced CD38 target expression
Yu, Tengteng
Chen, Hailin
Wen, Kenneth
Wang, Tingjian
Hsieh, Phillip
Smiths, Thomas
Samur, Mehmet
Xing, Lijie
Lin, Liang
Hao, Mu
Qiu, Lugui
Tai, Yu-Tzu
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S18 - S19

← 1 2 3 4 5 →